Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Big Cost Cuts At Dr Reddy’s, US Big Ticket Launch Progress Is Key

Executive Summary

Massive reorganization efforts are underway at Dr Reddy’s as it recalibrates costs; an antibiotics site is expected to be sold soon as part of these efforts and more may be in store. Management commentary was, however, upbeat around the growth outlook for the US business, with visibility of 15-20 launches in FY 2019.

Advertisement

Related Content

Dr Reddy’s CEO On Payer Dynamics, China Commitment And Disruption
Record Dr Reddy's US Launches In Q3 Set Tone For Earnings Pick Up?
US Suboxone Win Lifts Dr Reddy’s As Embattled Indivior Fights On
US Suboxone Win Lifts Dr Reddy’s As Embattled Indivior Fights On
Glenmark Re-Evaluates Complex Generics Basket, Won’t Be Part Of The 'Crowd'
Glenmark Re-Evaluates Complex Generics Basket, Won’t Be Part Of The 'Crowd'
Ex-Teva Executive To Steer Dr Reddy’s As COO

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123495

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel